为您找到"
xaf5
"相关结果约100,000,000个
XAF-5: a Adipocytes inhibitors Drug, Initially developed by Allergan UC, Now, its global highest R&D status is Phase 3, Mechanism: Adipocytes inhibitors, Therapeutic Areas: Endocrinology and Metabolic Disease, Active Indication: Obesity, Active Org.: Allergan UC.
Answer: XAF5 is a prostaglandin ointment that was developed by Topkine. Topkine was recently acquired by Allergan. The product is based on the observation that glaucoma patients using prostaglandin glaucoma drops are prone to developing atrophy of the eyelid tissues and loss of orbital volume.
Biotechnology company Topokine Therapeutics has initiated a Phase 2b/3 study of its lead product, XAF5 Ointment, for the reduction of steatoblepharon (undereye bags). Applied to the lower eyelids once nightly, the topical treatment penetrates the skin and acts pharmacologically on fat cells to shrink eye bags as an alternative to blepharoplasty surgery.
This randomized, placebo-controlled, double-masked, Phase 2b/Phase 3 study will assess the efficacy of two different concentrations of XAF5 Ointment for reduction of lower lid steatoblepharon (undereye bags).
XAF5 is a topical, fat-melting cream that will require a prescription in order to be dispensed and it aims to shrink the fat in the delicate and sometimes problematic under eye area… to start.
A treatment that painlessly melts away fat - known only by its experimental name of XAF5 - has been shown to significantly reduce bags under the eyes.
XAF5 is a glaucoma medication (like Latisse) turned eye-bag buster. Eye bags can come from genes, sleep deprivation, sun, age, sodium-rich foods, or allergies. Regardless, they blow up our beauty ...
XAF5 is a topical ocular ointment made by Topokine Theraeutics derived from prostaglandins that specifically targets under eye bags. XAF5 breaks down subcuntaneous (under the skin) eyelid fat that causes those pesky puffy under eye bags, or steatoblepharon in the dermatological world.
Allergan, the company behind the Botox brand of botulinum toxin, has acquired Topokine Therapeutics, a biotechnology company that develops topical medicines for fat reduction, for an upfront payment of USD$85 million. Topokine's key product is XAF5, a topical agent that pharmacologically shrinks the fat pads that cause under eye bags (known scientifically as steatoblepharon), currently in ...
Topokine Therapeutic's investigational XAF5 Ointment can safely and effective reduce excess eyelid fat, according to results from a Phase II trial.